Cardio Diagnostics Holdings Inc (CDIO)
0.86
+0.13
(+18.20%)
USD |
NASDAQ |
May 10, 11:22
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 18.57M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -58.66% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 6.277 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.00 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease. |
| URL | https://www.cardiodiagnosticsinc.com |
| Investor Relations URL | N/A |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 15, 2024 (est.) |
| Last Earnings Release | May. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Cardio Diagnostics Holdings Inc is a biotechnology company that makes cardiovascular disease prevention and early detection more accessible, personalized, and precise. The company was formed to further develop and commercialize a proprietary artificial intelligence-driven integrated Genetic-Epigenetic EngineTM for cardiovascular disease to become the leading medical technology company for enabling improved prevention, early detection, and assistance in the treatment of cardiovascular disease. |
| URL | https://www.cardiodiagnosticsinc.com |
| Investor Relations URL | N/A |
| HQ State/Province | Illinois |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | N/A |
| Next Earnings Release | May. 15, 2024 (est.) |
| Last Earnings Release | May. 15, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |